Silicon Valley Biosystems (SV Bio)

In early 2013, the Center for Individualized Medicine formalized a collaboration with SV Bio that focuses on whole-genome diagnostics and interpretation. It aims to make next-generation sequencing more accessible and beneficial for patients.

The Center for Individualized Medicine is contributing clinical and laboratory expertise and support, while SV Bio is providing clinical genome-interpretation services and clinical decision-support interfaces. Mayo will be implementing the SV Bio genome analytics pipeline to assist with the interpretation of whole-exome and whole-genome testing as a means to further enable individualized medicine.

The collaboration also includes Mayo Medical Laboratories, Mayo's reference laboratory that provides services worldwide, which is working with SV Bio to refine approaches to clinical genome interpretation.

Cancer Genetics, Inc.

IEstablished in 2013, start-up company OncoSpire Genomics accelerates and commercializes cancer research in the Center for Individualized Medicine’s Biomarker Discovery Program. The company focuses on hematological and urogenital cancers, with plans to expand as discoveries are made.

Biomarkers discovered by OncoSpire Genomics help provide individualize cancer care for patients at Mayo Clinic and around the world through new laboratory tests that offer more insight into how cancers progress and which medications will best treat the individual patient.

The company is an equal partnership between Mayo Clinic and Cancer Genetics, Inc. Cancer Genetics contributes operating capital; and Mayo contributes in-kind with research laboratory services, clinical experience and leading research expertise. The collaboration also includes Mayo Medical Laboratories, Mayo's reference laboratory that provides services worldwide for clinical validation and commercialization of new tests.

Mayo-Illinois Alliance for Technology-Based Healthcare

The Mayo-Illinois Alliance for Technology-Based Healthcare was founded in 2010 to advance research and clinical treatment options related to individualized medicine. It consists of:

  • Integrated research activities focusing on information-based medicine, genomics and point-of-care diagnostics
  • Entrepreneurial efforts to ensure full deployment and commercialization of educational and research outcomes
  • Innovative educational programs to train the next generation of clinicians and biomedical scientists

Specific collaborative activities include:

  • Microbiome-related studies, including the identification of microbial risk predictors for preterm birth
  • Applying microfluidics to epigenome-based activities
  • Optimizing bioinformatics algorithms for DNA sequence analysis
  • Developing an intensive seven-day computational medicine certificate class for allied health staff and fellows
  • University of Illinois undergraduates participating in the Mayo Clinic Summer Undergraduate Research Fellowship
  • Funding for Mayo Clinic and University of Illinois postdoctoral fellows to spend time at the other institution
  • Jointly developing and hosting the annual Individualizing Medicine Conference

Arizona State University

The Center for Individualized Medicine and Arizona State University (ASU) are working together on many fronts, including an initiative to jointly fund research projects that lead to commercialization opportunities. In February 2013, the first two $100,000 grants were awarded.

Other collaborative activities include:

  • Funding several other research studies with Mayo and ASU investigators, including a biomarker discovery project focused on protein microarray signatures for the detection of colorectal cancer
  • Funding a mass spectrometer for research into metallomics-related biomarkers
  • Working together to recruit the next chair of biomedical informatics at ASU

Translational Genomics Research Institute (TGen)

Investigators from Mayo Clinic and TGen, a Phoenix-based nonprofit research organization, have developed extensive individualized medicine-based collaborations spanning a variety of diseases, including multiple myeloma, breast cancer, melanoma, squamous cell carcinoma and pancreatic cancer.

As part of these collaborations, some Mayo and TGen researchers have received joint academic appointments at each others' organization.

In fall 2012, the Arizona Republic newspaper featured two stories about Mayo-TGen collaborative efforts:


The Center for Individualized Medicine, through its Information Technology Program, has joined Oracle's Strategic Development Partnership to collaborate on expanding Oracle's Translational Research Center product to centrally manage trillions of unique genetic variants for Mayo Clinic patients.

This partnership allows Mayo to provide strategic direction and influence on future functionality of the Translational Research Center solution. In addition, it allows Mayo early access to innovative technologies.

This resource will help the Center for Individualized Medicine manage genomic variants for multiplexed panels and whole-exome and whole-genome testing, leveraging the enormous amount of genomic data generated through laboratory testing of our patients. The goal is to develop a single infrastructure that can support individualized medicine activities spanning research and clinical practice, complete with privacy and security controls.